Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPureTech Regulatory News (PRTC)

Share Price Information for PureTech (PRTC)

Share Price is delayed by 15 minutes
Get Live Data
125.00    1.20 (0.97%)
Bid:
124.60
Ask:
125.00
Spread: 0.40 (0.321%)
Market Cap: £304.27m
PRTC Live PriceLast checked at - London Stock Exchange

Intraday PureTech Share Chart

Director/PDMR Shareholding

2 Nov 2020 16:35

RNS Number : 9964D
PureTech Health PLC
02 November 2020
 

 

PDMR DEALING NOTIFICATION

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Dr. John LaMattina

2

Reason for the notification

a)

Position/status

Director

b)

Initial notification/Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

PureTech Health plc

b)

LEI

213800LVPDNO2Z9T9I39

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

Ordinary shares of PureTech Health plc

ISIN GB00BY2Z0H74

b)

Nature of the transaction

A transfer of Ordinary Shares for nil consideration from Dr. LaMattina to the LaMattina Charitable Trust, of which Dr. LaMattina is a trustee.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

Nil

305,296

d)

Aggregated information

-

Aggregated volume

-

Price

 

Price

Aggregate Volume

Nil

305,296

e)

Date of the transaction

29 October 2020

f)

Place of the transaction

Outside of a trading venue

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHELLFBBFLEFBV
Date   Source Headline
13th May 20197:00 amRNSVedanta Grows Series C Financing to $45.5 Million
7th May 20197:00 amRNSVedanta Prevails in Important EU Patent Opposition
26th Apr 20197:15 amRNSPRTC's Karuna Files IPO Registration Statement
25th Apr 20197:00 amRNSGelesis Gets $10.6M Grant to Support Manufacturing
24th Apr 20197:00 amRNSFinal Results
17th Apr 20197:00 amRNSBoehringer Ingelheim & PRTC Immuno-oncology Collab
15th Apr 20197:00 amRNSGelesis Receives FDA Clearance for First Product
11th Apr 20191:00 pmRNSAkili Makes CFO & General Counsel Appointments
11th Apr 20197:05 amRNSGelesis Presents Data on Effects of High-Fat Diet
11th Apr 20197:00 amRNSSonde Completes $16M Series A Financing Round
2nd Apr 20197:00 amRNSPRTC Presents Immuno-Oncology Programmes at AACR
1st Apr 201912:05 pmRNSKaruna expands Series B financing to $80 million
25th Mar 20196:00 pmRNSGelesis Preclinical Data on Restoring Gut Barrier
25th Mar 20196:00 pmRNSGelesis New Clinical Data on Impact of Gelesis100
21st Mar 20197:00 amRNSGelesis to Present at Endocrine Society Annual Mtg
18th Mar 20197:00 amRNSKaruna Announces $68 Million Series B Financing
15th Mar 20197:00 amRNSNotice of Results
7th Mar 20197:00 amRNSAkili & Shionogi Deal in Taiwan/Japan $20M upfront
5th Mar 20197:00 amRNSKaruna Appoints Chief Financial Officer
22nd Feb 20194:41 pmRNSSecond Price Monitoring Extn
22nd Feb 20194:36 pmRNSPrice Monitoring Extension
21st Feb 20197:00 amRNSPRTC to Present at Two US Investor Conferences
15th Feb 20194:41 pmRNSSecond Price Monitoring Extn
15th Feb 20194:35 pmRNSPrice Monitoring Extension
14th Feb 20197:00 amRNSVor Raises $42M to Advance Leukaemia Treatment
28th Jan 20197:00 amRNSAlivio Partners to Advance Non-opioid Pain Therapy
23rd Jan 20196:08 pmRNSVedanta Immuno-oncology Candidate Published
2nd Jan 20197:00 amRNSTotal Voting Rights
28th Dec 201812:07 pmRNSSecond Price Monitoring Extn
28th Dec 201812:02 pmRNSPrice Monitoring Extension
24th Dec 20187:00 amRNSVedanta Biosciences Raise $27M Series C Financing
17th Dec 20187:00 amRNSVedanta Initiates Phase 2 Study for Lead Candidate
10th Dec 20187:00 amRNSVedanta & BMS Immuno-Oncology Collaboration
28th Nov 20187:00 amRNSVor Granted First-in-class Immuno-oncology Patent
27th Nov 20187:00 amRNSJanssen/Vedanta Phase 1 in IBD & $12M Milestone
26th Nov 20184:40 pmRNSSecond Price Monitoring Extn
26th Nov 20184:35 pmRNSPrice Monitoring Extension
22nd Nov 201812:07 pmRNSSecond Price Monitoring Extn
22nd Nov 201812:02 pmRNSPrice Monitoring Extension
16th Nov 201812:07 pmRNSSecond Price Monitoring Extn
16th Nov 201812:02 pmRNSPrice Monitoring Extension
14th Nov 201812:07 pmRNSSecond Price Monitoring Extn
14th Nov 201812:02 pmRNSPrice Monitoring Extension
13th Nov 201811:05 amRNSFull Gelesis Data Published in the Journal Obesity
7th Nov 20187:00 amRNSPRTC to Present at Jefferies 2018 in London
6th Nov 20181:00 pmRNSVedanta Presents Data on Immuno-Oncology Candidate
5th Nov 20187:00 amRNSGelesis to Present Full Data for Lead Candidate
31st Oct 201812:07 pmRNSSecond Price Monitoring Extn
31st Oct 201812:02 pmRNSPrice Monitoring Extension
17th Oct 20187:00 amRNSKaruna Adds Sage Therapeutics CEO to Board

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.